Cytokinetics, Incorporated
CYTK
$74.13
$0.680.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.53% | -12.57% | 40.22% | -127.86% | 16.73% |
| Total Depreciation and Amortization | 7.49% | 18.07% | 6.79% | 17.24% | -0.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.43% | 45.86% | -77.31% | 215.62% | 68.27% |
| Change in Net Operating Assets | -11,425.57% | 88.13% | -108.19% | 144.08% | -882.34% |
| Cash from Operations | -9.89% | -1.97% | -32.69% | 16.17% | 2.57% |
| Capital Expenditure | 26.91% | -5.07% | 39.66% | -125.67% | 26.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -431.96% | 331.01% | -6.37% | -208.06% | -48.91% |
| Cash from Investing | -448.47% | 304.37% | -0.30% | -234.22% | -50.09% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -39.23% | -0.48% | 99.33% | -14,918.87% | 6.45% |
| Issuance of Common Stock | 6,934.65% | -22.54% | 111.22% | 2.82% | -11.84% |
| Repurchase of Common Stock | -76.69% | 31.12% | -69.58% | -40.08% | -3,853.85% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | 10,104.08% | -92.98% | -66.50% | 320.80% | 1,551.94% |
| Foreign Exchange rate Adjustments | -23.19% | -352.88% | 315.22% | 106.74% | -152.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,612.97% | 107.11% | -167.72% | 5,990.87% | 111.79% |